Skip to content
Molecules
SEKISUI XenoTech DD Blog Logo

COVID-19 Updates

As a global Life Sciences and Healthcare company, SEKISUI XenoTech recognizes the seriousness of the Coronavirus Pandemic. We are constantly monitoring this worldwide situation, and are taking action to protect our employees and address the growing concerns at the global and local level.
 
Recently, local jurisdictions for our Kansas City based operations have placed Emergency Orders concerning residents and actions around the Coronavirus pandemic. Because of our global support for  bringing life-saving therapies to the market, SEKISUI XenoTech’s Kansas City based facility has been designated an “Essential Business.” Therefore we are not closing our operations. However, we are adhering to strict social distancing restrictions that require many functions to be limited. There will be a reduction in the amount of personnel that will work in our building at one time and laboratory activities for services and the preparation of custom test systems will be somewhat trimmed. Importantly, in these uncertain times, our Regulatory and Scientific Consulting resources are fully available.  
 
As a global operation, we maintain similar capabilities in our sister lab located in Tokai, Japan, which remains open and unaffected. All studies and service capabilities that exist within our North American operations are also available through this Japan location.
 
Remote infrastructure for non-laboratory business operations has been established and Study Managers, Study Directors and Business Development personnel are all available for any and all discussion. Please contact them directly or through our main lines:
Phone: +1.913.438.7450
Toll-Free: 1-877-588-7530 (North America)
E-Mail: info@xenotechllc.com
 


Previous Update Posted:  18 March 2020 For over 25 years, we have set the industry standard for improving safety in drug development. That reliable support can’t—and won’t—halt due to COVID-19.

Our resolve to provide the highest-quality services and test systems remains solid and true. It is in our DNA to constantly review our practices in order to respond with responsible and ethical action, especially in the face of global crisis. Our clients can trust that we are doing everything possible to make sure timelines and product availability are minimally affected.

We are fortunate to be located in the heart of the American Midwest, where it is comparatively easier for our teams to avoid crowded metropolitan areas and stay safe. Our flexible work environment, which embraces working from home, accommodates the current “social distancing” obligation and we are taking appropriate steps to further augment internal sanitation and anti-contamination practices to ensure that our laboratories remain a safe, clean space for our team to continue carrying out contracted studies and preparing the high-quality test systems our clients rely on.

We’re here to help you through all of the ups and downs in your drug’s development– during this challenging time our sales and customer support staff are focused on stability, maintaining close contact and continuing to provide our signature, outstanding service through all available channels. As a global company, our business is built on consistent engagement with the international drug development community and a strong reputation for reliable communication throughout contracted studies. In lieu of in-person meetings and events we are available around the clock to answer questions and support your unique needs. In addition, you’ll soon see increased online availability of fresh educational resources suited to our global clientele.

Via online platforms, we will bring the science to you. From anywhere, our customers can access exclusive content and participate in live webinars with Q&A sessions. New webinars are in the works covering important topics such as the latest regulatory updates, how to select the right test systems for your DMPK studies, intricacies of the intersection between ADME and toxicology, and others. Please stay tuned for announcements and scheduling of these webinars over the next few weeks. Other novel content scheduled to premiere at exhibitions and tradeshows will be available for download from our website. Furthermore, we are pushing full-steam ahead to supplement new research with presentations filled with the vital context and in-depth explanation normally available at a live poster exhibit. The bright side is that now you won’t have had to purchase a plane ticket to reap those benefits! Our experts have decades of experience. Sharing the fruits of their labor will not cease because the conference schedule is on hold.

Keep an eye on our social media (LinkedInFacebook, and Twitter) and sign up for email notifications to access these new resources (and more) as we make them available. If you find yourself in need of ways to stay engaged from your home or office, check out our extensive collection of scientific posterspublicationswebinars, and more on our website.

Stay safe in these trying circumstances, and take peace of mind knowing that our unwavering commitment to safety will keep the development of safe, effective compounds moving forward.

– Your SEKISUI XenoTech Team

About the Authors

Michael Millhollen received his bachelor's degree in Visual Communications from the University of Kansas and has over 20 years of experience in marketing and communications. As Global Marketing Manager, he is dedicated to the objective of sharing SEKISUI XenoTech’s scientific expertise and knowledge with scientists around the world.

Subscribe to our Newsletter

Stay up to date with our news, events and research

In vitro pipette test article treatment
005 International Messaging Created with Sketch.

Do you have a question or a request for upcoming blog content?

We love to get your feedback

A scientist utlilizing a microplate